DANONE (BSN.DE) Fundamental Analysis & Valuation
FRA:BSN • FR0000120644
Current stock price
69.16 EUR
+0.4 (+0.58%)
Last:
This BSN.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. BSN.DE Profitability Analysis
1.1 Basic Checks
- BSN had positive earnings in the past year.
- In the past year BSN had a positive cash flow from operations.
- Each year in the past 5 years BSN has been profitable.
- BSN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- BSN has a Return On Assets (4.03%) which is in line with its industry peers.
- Looking at the Return On Equity, with a value of 10.73%, BSN is in the better half of the industry, outperforming 60.66% of the companies in the same industry.
- BSN has a better Return On Invested Capital (7.75%) than 65.57% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for BSN is in line with the industry average of 7.13%.
- The last Return On Invested Capital (7.75%) for BSN is above the 3 year average (7.51%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.03% | ||
| ROE | 10.73% | ||
| ROIC | 7.75% |
ROA(3y)3.48%
ROA(5y)3.34%
ROE(3y)9.16%
ROE(5y)8.75%
ROIC(3y)7.51%
ROIC(5y)7.21%
1.3 Margins
- The Profit Margin of BSN (6.66%) is better than 63.93% of its industry peers.
- In the last couple of years the Profit Margin of BSN has declined.
- BSN has a Operating Margin of 13.43%. This is amongst the best in the industry. BSN outperforms 88.52% of its industry peers.
- BSN's Operating Margin has been stable in the last couple of years.
- The Gross Margin of BSN (50.62%) is better than 85.25% of its industry peers.
- In the last couple of years the Gross Margin of BSN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.43% | ||
| PM (TTM) | 6.66% | ||
| GM | 50.62% |
OM growth 3Y3.21%
OM growth 5Y-0.93%
PM growth 3Y24.9%
PM growth 5Y-4.13%
GM growth 3Y3.2%
GM growth 5Y1.04%
2. BSN.DE Health Analysis
2.1 Basic Checks
- BSN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- BSN has less shares outstanding than it did 1 year ago.
- BSN has less shares outstanding than it did 5 years ago.
- BSN has a worse debt/assets ratio than last year.
2.2 Solvency
- BSN has an Altman-Z score of 2.39. This is not the best score and indicates that BSN is in the grey zone with still only limited risk for bankruptcy at the moment.
- BSN has a Altman-Z score of 2.39. This is comparable to the rest of the industry: BSN outperforms 59.02% of its industry peers.
- BSN has a debt to FCF ratio of 5.29. This is a neutral value as BSN would need 5.29 years to pay back of all of its debts.
- BSN's Debt to FCF ratio of 5.29 is fine compared to the rest of the industry. BSN outperforms 68.85% of its industry peers.
- BSN has a Debt/Equity ratio of 0.73. This is a neutral value indicating BSN is somewhat dependend on debt financing.
- With a Debt to Equity ratio value of 0.73, BSN is not doing good in the industry: 60.66% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.73 | ||
| Debt/FCF | 5.29 | ||
| Altman-Z | 2.39 |
ROIC/WACC1.22
WACC6.36%
2.3 Liquidity
- A Current Ratio of 0.90 indicates that BSN may have some problems paying its short term obligations.
- With a Current ratio value of 0.90, BSN is not doing good in the industry: 78.69% of the companies in the same industry are doing better.
- A Quick Ratio of 0.75 indicates that BSN may have some problems paying its short term obligations.
- Looking at the Quick ratio, with a value of 0.75, BSN is in line with its industry, outperforming 40.98% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.9 | ||
| Quick Ratio | 0.75 |
3. BSN.DE Growth Analysis
3.1 Past
- BSN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.68%.
- BSN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 2.61% yearly.
- The Revenue has decreased by -0.34% in the past year.
- The Revenue has been growing slightly by 2.93% on average over the past years.
EPS 1Y (TTM)4.68%
EPS 3Y3.47%
EPS 5Y2.61%
EPS Q2Q%3.28%
Revenue 1Y (TTM)-0.34%
Revenue growth 3Y-0.46%
Revenue growth 5Y2.93%
Sales Q2Q%-0.54%
3.2 Future
- Based on estimates for the next years, BSN will show a small growth in Earnings Per Share. The EPS will grow by 7.81% on average per year.
- The Revenue is expected to grow by 4.25% on average over the next years.
EPS Next Y6.56%
EPS Next 2Y6.99%
EPS Next 3Y7.19%
EPS Next 5Y7.81%
Revenue Next Year2.57%
Revenue Next 2Y3.27%
Revenue Next 3Y3.55%
Revenue Next 5Y4.25%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. BSN.DE Valuation Analysis
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 18.20 indicates a rather expensive valuation of BSN.
- BSN's Price/Earnings ratio is in line with the industry average.
- Compared to an average S&P500 Price/Earnings ratio of 26.78, BSN is valued a bit cheaper.
- With a Price/Forward Earnings ratio of 17.08, BSN is valued on the expensive side.
- The rest of the industry has a similar Price/Forward Earnings ratio as BSN.
- BSN's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.54.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.2 | ||
| Fwd PE | 17.08 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BSN is on the same level as its industry peers.
- BSN's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. BSN is cheaper than 70.49% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.29 | ||
| EV/EBITDA | 9.52 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BSN does not grow enough to justify the current Price/Earnings ratio.
- BSN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.78
PEG (5Y)6.96
EPS Next 2Y6.99%
EPS Next 3Y7.19%
5. BSN.DE Dividend Analysis
5.1 Amount
- BSN has a Yearly Dividend Yield of 3.28%. Purely for dividend investing, there may be better candidates out there.
- Compared to an average industry Dividend Yield of 2.92, BSN pays a bit more dividend than its industry peers.
- BSN's Dividend Yield is rather good when compared to the S&P500 average which is at 1.83.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.28% |
5.2 History
- The dividend of BSN has a limited annual growth rate of 0.46%.
Dividend Growth(5Y)0.46%
Div Incr Years4
Div Non Decr Years5
5.3 Sustainability
- 75.94% of the earnings are spent on dividend by BSN. This is not a sustainable payout ratio.
- BSN's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP75.94%
EPS Next 2Y6.99%
EPS Next 3Y7.19%
BSN.DE Fundamentals: All Metrics, Ratios and Statistics
FRA:BSN (4/10/2026, 7:00:00 PM)
69.16
+0.4 (+0.58%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)02-20 2026-02-20/bmo
Earnings (Next)04-22 2026-04-22
Inst Owners55.19%
Inst Owner ChangeN/A
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap47.12B
Revenue(TTM)27.28B
Net Income(TTM)1.82B
Analysts75.76
Price Target81.41 (17.71%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.28% |
Yearly Dividend2.15
Dividend Growth(5Y)0.46%
DP75.94%
Div Incr Years4
Div Non Decr Years5
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.79%
PT rev (3m)0.69%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.89%
EPS NY rev (3m)-3.3%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)-0.84%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.2 | ||
| Fwd PE | 17.08 | ||
| P/S | 1.73 | ||
| P/FCF | 17.29 | ||
| P/OCF | 12.47 | ||
| P/B | 2.79 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.52 |
EPS(TTM)3.8
EY5.49%
EPS(NY)4.05
Fwd EY5.85%
FCF(TTM)4
FCFY5.78%
OCF(TTM)5.55
OCFY8.02%
SpS40.04
BVpS24.83
TBVpS-9.13
PEG (NY)2.78
PEG (5Y)6.96
Graham Number46.07
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.03% | ||
| ROE | 10.73% | ||
| ROCE | 12.04% | ||
| ROIC | 7.75% | ||
| ROICexc | 9.68% | ||
| ROICexgc | 76.66% | ||
| OM | 13.43% | ||
| PM (TTM) | 6.66% | ||
| GM | 50.62% | ||
| FCFM | 9.99% |
ROA(3y)3.48%
ROA(5y)3.34%
ROE(3y)9.16%
ROE(5y)8.75%
ROIC(3y)7.51%
ROIC(5y)7.21%
ROICexc(3y)9.24%
ROICexc(5y)8.74%
ROICexgc(3y)70.2%
ROICexgc(5y)59.95%
ROCE(3y)11.59%
ROCE(5y)10.94%
ROICexgc growth 3Y20.15%
ROICexgc growth 5Y16.9%
ROICexc growth 3Y6.6%
ROICexc growth 5Y4.3%
OM growth 3Y3.21%
OM growth 5Y-0.93%
PM growth 3Y24.9%
PM growth 5Y-4.13%
GM growth 3Y3.2%
GM growth 5Y1.04%
F-Score7
Asset Turnover0.61
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.73 | ||
| Debt/FCF | 5.29 | ||
| Debt/EBITDA | 2.46 | ||
| Cap/Depr | 77.86% | ||
| Cap/Sales | 3.87% | ||
| Interest Coverage | 21.06 | ||
| Cash Conversion | 75.3% | ||
| Profit Quality | 150.06% | ||
| Current Ratio | 0.9 | ||
| Quick Ratio | 0.75 | ||
| Altman-Z | 2.39 |
F-Score7
WACC6.36%
ROIC/WACC1.22
Cap/Depr(3y)69.82%
Cap/Depr(5y)67.75%
Cap/Sales(3y)3.44%
Cap/Sales(5y)3.55%
Profit Quality(3y)197.16%
Profit Quality(5y)188.14%
High Growth Momentum
Growth
EPS 1Y (TTM)4.68%
EPS 3Y3.47%
EPS 5Y2.61%
EPS Q2Q%3.28%
EPS Next Y6.56%
EPS Next 2Y6.99%
EPS Next 3Y7.19%
EPS Next 5Y7.81%
Revenue 1Y (TTM)-0.34%
Revenue growth 3Y-0.46%
Revenue growth 5Y2.93%
Sales Q2Q%-0.54%
Revenue Next Year2.57%
Revenue Next 2Y3.27%
Revenue Next 3Y3.55%
Revenue Next 5Y4.25%
EBIT growth 1Y3.01%
EBIT growth 3Y2.73%
EBIT growth 5Y1.96%
EBIT Next Year36.46%
EBIT Next 3Y14.84%
EBIT Next 5Y11.54%
FCF growth 1Y-6.26%
FCF growth 3Y9.25%
FCF growth 5Y6.33%
OCF growth 1Y-1.31%
OCF growth 3Y8.46%
OCF growth 5Y4.96%
DANONE / BSN.DE Fundamental Analysis FAQ
What is the fundamental rating for BSN stock?
ChartMill assigns a fundamental rating of 5 / 10 to BSN.DE.
What is the valuation status for BSN stock?
ChartMill assigns a valuation rating of 4 / 10 to DANONE (BSN.DE). This can be considered as Fairly Valued.
Can you provide the profitability details for DANONE?
DANONE (BSN.DE) has a profitability rating of 7 / 10.
What is the financial health of DANONE (BSN.DE) stock?
The financial health rating of DANONE (BSN.DE) is 3 / 10.
Can you provide the dividend sustainability for BSN stock?
The dividend rating of DANONE (BSN.DE) is 6 / 10 and the dividend payout ratio is 75.94%.